Insulin-like growth factor-1: A possible marker for emotional and cognitive disturbances, and treatment effectiveness in major depressive disorder

Annals of General Psychiatry

Volumn 16, Issue 1, 2017, Pages

  Levada, Oleg A ^a   Troyan, Alexandra S ^a  

^a Ministry of Health of Ukraine   (Ukraine)

Author keywords

Antidepressants; Cognitive dysfunction; Depression; Growth factors; IGF 1; MDD

Indexed keywords

ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; NEUROTROPHIN; SOMATOMEDIN C;

AGE; COGNITIVE DEFECT; DISEASE COURSE; DISEASE MARKER; EMOTIONAL DISORDER; GENDER; HEALTH STATUS; HUMAN; MAJOR DEPRESSION; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; TREATMENT RESPONSE;

EID: 85032335681     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/s12991-017-0161-3     Document Type: Review

References (58)

1. Kessler RS, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095-105.
2. Vandeleur CL, Fassassi S, Castelao E, Glaus J, Strippoli MF, Lasserre AM, et al. Prevalence and correlates of DSM-5 major depressive and related disorders in the community. Psychiatry Res. 2017;250:50-8.
3. McIntyre RS, Xiao HX, Syeda K, Vinberg M, Carvalho AF, Mansur RB, et al. The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder. CNS Drugs. 2015;29:577-89.
4. Baune BT, Miller R, McAfoose J, Johnson M, Quirk F, Mitchell D. The role of cognitive impairment in general functioning in major depression. Psychiatry Res. 2010;176:183-9.
5. Lam RW, Kennedy SH, Mclntyre RS, Khullar A. Cognitive dysfunction in major depressive disorder: effects on psychosocial functioning and implications for treatment. Can J Psychiatry. 2014;59:649-54.
6. Lee RS, Hermens DF, Porter MA, Redoblado-Hodge MA. A meta-analysis of cognitive deficits in first-episode major depressive disorder. J Affect Disord. 2012;140:113-24.
7. Bora E, Harrison BJ, Yücel M, Pantelis C. Cognitive impairment in euthymic major depressive disorder: a meta-analysis. Psychol Med. 2013;43:2017-26.
8. Bortolato B, Carvalho AF, McIntyre RS. Cognitive dysfunction in major depressive disorder: a state-of-the-art clinical review. CNS Neurol Disord Drug Targets. 2014;13:1804-18.
9. Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med. 2014;44:2029-40.
10. Papazacharias A, Nardini M. The relationship between depression and cognitive deficits. Psychiatr Danub. 2012;24(Suppl 1):S179-82.
11. Kim HK, Nunes PV, Oliveira KC, Young LT, Lafer B. Neuropathological relationship between major depression and dementia: a hypothetical model and review. Prog Neuropsychopharmacol Biol Psychiatry. 2016;67:51-7.
12. Carvalho AF, Miskowiak KK, Hyphantis TN, Kohler CA, Alves GS, Bortolato B, et al. Cognitive dysfunction in depression-pathophysiology and novel targets. CNS Neurol Disord Drug Targets. 2014;13:1819-35.
13. Darcet F, Gardier AM, Gaillard R, David DJ, Guilloux JP. Cognitive dysfunction in major depressive disorder. A translational review in animal models of the disease. Pharmaceuticals. 2016;9(1):9.
14. Li Y, Pehrson AL, Waller JA, Dale E, Sanchez C, Gulinello M. A critical evaluation of the activity-regulated cytoskeleton-associated protein (Arc/Arg3.1)'s putative role in regulating dendritic plasticity, cognitive processes, and mood in animal models of depression. Front Neurosci. 2015;9:279.
15. Rial D, Lemos C, Pinheiro H, Duarte JM, Gonçalves FQ, Real JI, et al. Depression as a glial-based synaptic dysfunction. Front Cell Neurosci. 2016;9:521.
16. Sweatt JD. Neural plasticity and behavior-sixty years of conceptual advances. J Neurochem. 2016;139(Suppl 2):179-99.
17. Szczȩsny E, Slusarczyk J, Głombik K, Budziszewska B, Kubera M, Lasoń W, et al. Possible contribution of IGF-1 to depressive disorder. Pharmacol Rep. 2013;65:1622-31.
18. Suh HS, Zhao ML, Derico L, Choi N, Lee SC. Insulin-like growth factor 1 and 2 (IGF1, IGF2) expression in human microglia: differential regulation by inflammatory mediators. J Neuroinflamm. 2013;10:37.
19. Duman R. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromol Med. 2004;5:11-25.
20. Mitre M, Mariga A, Chao MV. Neurotrophin signalling: novel insights into mechanisms and pathophysiology. Clin Sci. 2017;131:13-23.
21. Matheny RW Jr, Nindl BC, Adamo ML. Minireview: mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. Endocrinology. 2010;151:865-75.
22. Annunziata M, Granata R, Ghigo E. The IGF system. Acta Diabetol. 2011;48:1-9.
23. Werner H, LeRoith D. Insulin and insulin-like growth factor receptors in the brain: physiological and pathological aspects. Eur Neuropsychopharmacol. 2014;24:1947-53.
24. Torres-Aleman I. Toward a comprehensive neurobiology of IGF-I. Dev Neurobiol. 2010;70:384-96.
25. Russo VC, Gluckman PD, Feldman EL, Werther GA. The insulin-like growth factor system and its pleiotropic functions in brain. Endocr Rev. 2005;26:916-43.
26. Basta-Kaim A, Szczesny E, Glombik K, Stachowicz K, Slusarczyk J, Nalepa I, et al. Prenatal stress affects insulin-like growth factor-1 (IGF-1) level and IGF-1 receptor phosphorylation in the brain of adult rats. Eur Neuropsychopharmacol. 2014;24:1546-56.
27. Trojan E, Głombik K, Ślusarczyk J, Budziszewska B, Kubera M, Roman A, et al. The beneficial impact of antidepressant drugs on prenatal stress-evoked malfunction of the insulin-like growth factor-1 (IGF-1) protein family in the olfactory bulbs of adult rats. Neurotox Res. 2016;29:288-98.
28. Trejo JL, Llorens-Martín MV, Torres-Alemán I. The effects of exercise on spatial learning and anxiety-like behavior are mediated by an IGF-I-dependent mechanism related to hippocampal neurogenesis. Mol Cell Neurosci. 2008;37:402-11.
29. Das SK, Barhwal K, Hota SK, Thakur MK, Srivastava RB. Disrupting monotony during social isolation stress prevents early development of anxiety and depression like traits in male rats. BMC Neurosci. 2015;16:2.
30. Beck KD, Powell-Braxton L, Widmer H-R, Valverde J, Hefti F. Igf1 gene disruption results in reduced brain size, CNS hypomyelination, and loss of hippocampal granule and striatal parvalbumin-containing neurons. Neuron. 1995;14:717-30.
31. Lichtenwalner RJ, Forbes ME, Bennett SA, Lynch CD, Sonntag WE, Riddle DR. Intracerebroventricular infusion of insulin-like growth factor-I ameliorates the age-related decline in hippocampal neurogenesis. Neuroscience. 2001;107:603-13.
32. Crupi R, Cuzzocrea S. Neuroinflammation and Immunity: a new pharmacological target in depression. CNS Neurol Disord Drug Targets. 2016;15:464-76.
33. Park SE, Dantzer R, Kelley KW, McCusker RH. Central administration of insulin-like growth factor-I decreases depressive-like behavior and brain cytokine expression in mice. J Neuroinflamm. 2011;8:12.
34. Puzik A, Rupp J, Tröger B, Göpel W, Herting E, Härtel C. Insulin-like growth factor-I regulates the neonatal immune response in infection and maturation by suppression of IFN-g. Cytokine. 2012;60:369-76.
35. Bot M, Milaneschi Y, Penninx BW, Drent ML. Plasma insulin-like growth factor I levels are higher in depressive and anxiety disorders, but lower in antidepressant medication users. Psychoneuroendocrinology. 2016;68:148-55.
36. Rosso G, Zanardini R, Chiodelli DF, Ferrari C, Gennarelli M, Bocchio-Chiavetto L. Serum levels of insulin-like growth factor-1 and obsessive-compulsive disorder: a case-control study. Neuropsychobiology. 2016;74:15-21.
37. Sharma AN, da Costa e Silva BF, Soares JC, Carvalho AF, Quevedo J. Role of trophic factors GDNF, IGF-1 and VEGF in major depressive disorder: a comprehensive review of human studies. J Affect Disord. 2016;197:9-20.
38. Tu KY, Wu MK, Chen YW, Lin PY, Wang HY, Wu CK, et al. Significantly higher peripheral insulin-like growth factor-1 levels in patients with major depressive disorder or bipolar disorder than in healthy controls: a meta-analysis and review under guideline of PRISMA. Medicine. 2016;95:e2411.
39. Chigogora S, Zaninotto P, Kivimaki M, Steptoe A, Batty GD. Insulin-like growth factor 1 and risk of depression in older people: the English Longitudinal Study of Ageing. Transl Psychiatry. 2016;6:e898.
40. Van Varsseveld NC, Van Bunderen CC, Sohl E, Comijs HC, Penninx BW, Lips P, et al. Serum insulin-like growth factor 1 and late-life depression: a population-based study. Psychoneuroendocrinology. 2015;54:31-40.
41. Rusch HL, Guardado P, Baxter T, Mysliwiec V, Gill JM. Improved sleep quality is associated with reductions in depression and PTSD arousal symptoms and increases in IGF-1 concentrations. J Clin Sleep Med. 2015;11:615-23.
42. Kopczak A, Stalla GK, Uhr M, et al. IGF-I in major depression and antidepressant treatment response. Eur Neuropsychopharmacol. 2015;25:864-72.
43. Krogh J, Rostrup E, Thomsen C, Elfving B, Videbech P, Nordentoft M. The effect of exercise on hippocampal volume and neurotrophins in patients with major depression-a randomized clinical trial. J Affect Disord. 2014;165:24-30.
44. Sievers C, Auer MK, Klotsche J, Athanasoulia AP, Schneider HJ, Nauck M, et al. IGF-I levels and depressive disorders: results from the Study of Health in Pomerania (SHIP). Eur Neuropsychopharmacol. 2014;24:890-6.
45. Lin F, Suhr J, Diebold S, Heffner KL. Associations between depressive symptoms and memory deficits vary as a function of insulin-like growth factor (IGF-1) levels in healthy older adults. Psychoneuroendocrinology. 2014;42:118-23.
46. Emeny RT, Bidlingmaier M, Lacruz ME, Linkohr B, Peters A, Reincke M, Ladwig KH. Mind over hormones: sex differences in associations of well-being with IGF-I, IGFBP-3 and physical activity in the KORA-age study. Exp Gerontol. 2014;59:58-64.
47. Li SX, Liu LJ, Xu LZ, et al. Diurnal alterations in circadian genes and peptides in major depressive disorder before and after escitalopram treatment. Psychoneuroendocrinology. 2013;38:2789-99.
48. Palomino A, Gonzalez-Pinto A, Martinez-Cengotitabengoa M, et al. Relationship between negative symptoms and plasma levels of insulin-like growth factor 1 in first-episode schizophrenia and bipolar disorder patients. Prog Neuropsychopharmacol Biol Psychiatry. 2013;44:29-33.
49. Weber-Hamann B, Blum WF, Kratzsch J, Gilles M, Heuser I, Deuschle M. Insulin-like growth factor-I (IGF-I) serum concentrations in depressed patients: relationship to saliva cortisol and changes during antidepressant treatment. Pharmacopsychiatry. 2009;42:23-8.
50. Rueda Alfaro S, Serra-Prat M, Palomera E, Falcon I, Cadenas I, Boquet X, Puig Domingo M. Hormonal determinants of depression and cognitive function in independently-living elders. Endocrinol Nutr. 2008;55:396-401.
51. Michelson D, Amsterdam J, Apter J, Fava M, Londborg P, Tamura R, Pagh L. Hormonal markers of stress response following interruption of selective serotonin reuptake inhibitor treatment. Psychoneuroendocrinology. 2000;25:169-77.
52. Franz B, Buysse DJ, Cherry CR, Gray NS, Grochocinski VJ, Frank E, et al. Insulin-like growth factor 1 and growth hormone binding protein in depression: a preliminary communication. J Psychiatr Res. 1999;33:121-7.
53. Deuschle M, Blum WF, Strasburger CJ, Schweiger U, Weber B, Körner A, et al. Insulin-like growth factor-I. IGF-I) plasma concentrations are increased in depressed patients. Psychoneuroendocrinology. 1997;22:493-503.
54. Michelson D, Stratakis C, Hill L, et al. Bone mineral density in women with depression. N Engl J Med. 1996;335:1176-81.
55. Lesch KP, Rupprecht R, Müller U, Pfüller H, Beckmann H. Insulin-like growth factor I in depressed patients and controls. Acta Psychiatr Scand. 1988;78:684-8.
56. Mitschelen M, Yan H, Farley JA, Warrington JP, Han S, Hereñú CB, et al. Long-term deficiency of circulating and hippocampal insulin-like growth factor I induces depressive behavior in adult mice: a potential model of geriatric depression. Neuroscience. 2011;185:50-60.
57. Clemmons DR. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem. 2011;57:555-9.
58. Bancos I, Algeciras-Schimnich A, Grebe SK, Donato LJ, Nippoldt TB, Erickson D. Evaluation of variables influencing the measurement of insulin-like growth factor-1. Endocr Pract. 2014;20:421-6.